Imperative Care is a biotechnology company that develops treatments intended for ischemic or vascular diseases including stroke, pulmonary embolism, and heart disease. Imperative Care was founded in 2015 and is headquartered in Campbell, CA. Striving to take a holistic view of conditions related to vascular disease, Imperative Care aims to research the entire lifecycle of blood-blocking conditions including detection, early disease stages, life-threatening incidents, and recovery.
Imperative Care is a privately held company and is not publicly traded, therefore investing in Imperative Care pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
Can you sell shares of Imperative Care before it goes public?
You can seek to sell your shares in Imperative Care while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
What is the pre-IPO value of my Imperative Care shares?
To determine the value of your Imperative Care shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Imperative Care shares. You can also learn more about how to sell your private shares before getting started.
Is Imperative Care a publicly traded company?
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
To learn more about Imperative Care potential IPO
Will Imperative Care go IPO?
Imperative Care has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
What is Imperative Care’s IPO price?
The Imperative Care IPO price does not exist at this time, as Imperative Care is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Imperative Care register for Forge Markets, today.
When was Imperative Care founded?
Imperative Care was founded in 2015.
What is Imperative Care funding to date?
Imperative Care has raised $898.94MM to date.
Who are Imperative Care’s major investors?
D1 Capital Partners
Montreux Equity Partners
Rock Springs Capital
Ally Bridge Group
Ascension Ventures
AMED Ventures
Catalio Capital Management
HealthCor Partners Management
Bain Capital Life Sciences
Delos Capital Partners
Incept
Pura Vida Investments
Intai Technology
Innovatus Capital Partners
3H Health Investment
Imperative Care Funding Rounds and Valuation
Funding History Chart
Funding Round Details
Funding Date
Share Class
Amount Raised
Price per Share
Post-Money Valuation
Key Investors
07/25/2024
Series E-3
$25MM
$xx.xx
$1.66B
Ally Bridge Group, D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital, Innovatus Capital Partners, Pura Vida Investments, Catalio Capital Management, HealthCor, Montreux Growth Partners, INTAI Technology
Price per Share
$xx.xx
Shares Outstanding
3,639,540
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
700.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group, D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital, Innovatus Capital Partners, Pura Vida Investments, Catalio Capital Management, HealthCor, Montreux Growth Partners, INTAI Technology
07/25/2024
Series E-2
$50MM
$xx.xx
$1.66B
Ally Bridge Group, D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital, Innovatus Capital Partners, Pura Vida Investments, Catalio Capital Management, HealthCor, Montreux Growth Partners, INTAI Technology
Price per Share
$xx.xx
Shares Outstanding
7,279,080
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
700.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group, D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital, Innovatus Capital Partners, Pura Vida Investments, Catalio Capital Management, HealthCor, Montreux Growth Partners, INTAI Technology
07/25/2024
Series E-1
$75MM
$xx.xx
$1.66B
Ally Bridge Group, D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital, Innovatus Capital Partners, Pura Vida Investments, Catalio Capital Management, HealthCor, Montreux Growth Partners, INTAI Technology
Price per Share
$xx.xx
Shares Outstanding
10,918,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
700.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group, D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital, Innovatus Capital Partners, Pura Vida Investments, Catalio Capital Management, HealthCor, Montreux Growth Partners, INTAI Technology
07/15/2021
Series D
$260MM
$xx.xx
$1.35B
D1 Capital Partners, HealthCor Investments, Innovatus Capital Partners, Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, AMED Ventures
Price per Share
$xx.xx
Shares Outstanding
37,851,216
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
700.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
D1 Capital Partners, HealthCor Investments, Innovatus Capital Partners, Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, AMED Ventures
11/26/2019
Series C
$86MM
$xx.xx
$266.49MM
Rock Springs Capital, Incept, Delos Capital, Bain Capital Life Sciences, Ascension Ventures, Ally Bridge Group
Price per Share
$xx.xx
Shares Outstanding
43,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
700.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Rock Springs Capital, Incept, Delos Capital, Bain Capital Life Sciences, Ascension Ventures, Ally Bridge Group
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
November Private Market Update
